Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2016-03-29 Annual Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
20160329_PR_FY Results 2015_FINAL_FR.pdf
Annual Report Classification · 95% confidence The document is a comprehensive financial report for Bone Therapeutics for the fiscal year 2015. It includes detailed financial statements (income statement, balance sheet), management's discussion and analysis of operational and financial results, and outlook for the upcoming year. While it mentions an upcoming conference call, the document itself contains the substantive financial data and analysis required for an annual or interim report. Given it covers the full fiscal year 2015, it is classified as an Annual Report (10-K equivalent for international reporting). FY 2015
2016-03-29 French
20160329_PR_FY Results 2015_DEF_NL.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive annual financial results announcement for Bone Therapeutics for the fiscal year 2015. It includes detailed financial highlights, operational progress, management commentary, and a summary of the balance sheet and income statement. While it serves as an announcement, it contains substantive financial data and analysis, distinguishing it from a simple report publication announcement (RPA). It is not a full 10-K (which is a specific US regulatory filing), but rather an interim/annual financial report for a European company, fitting the 'Interim / Quarterly Report' (IR) category as it provides the actual financial statements and analysis for the period. FY 2015
2016-03-29 Dutch
Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
Regulatory Filings Classification · 95% confidence The document is a press release dated March 29, 2016, announcing 'initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis.' It details preliminary clinical data (pain reduction, bone turnover markers) and includes commentary from the CEO. The presence of 'Regulated information' headers and the format strongly suggest an official company announcement regarding recent operational/clinical progress. This is characteristic of an Earnings Release (ER) if it were quarterly results, but since it is focused specifically on clinical trial data updates, it fits best under the general category of an announcement of important company news. Given the options, it is not a full Annual Report (10-K), a formal Audit Report (AR), or a transcript (CT). It is a specific announcement of results, which aligns closely with the function of an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it is a detailed announcement of clinical trial results, which often accompanies or substitutes for a formal earnings report in biotech/pharma, and it is not merely announcing the *publication* of a report (RPA), ER is the most appropriate fit for a significant, period-specific operational update, even if not strictly quarterly financial earnings. If ER is interpreted strictly as financial earnings, then RNS (Regulatory Filings) is the fallback. Given the context of reporting clinical trial results, which are often released alongside or instead of quarterly financials, ER is a strong candidate for a major operational update. However, looking closely at the definitions, ER is for 'periodical financial results (key highlights only)'. This document is about clinical trial results. Since it is a formal announcement of material, non-financial operational results, and it is not a proxy statement, director dealing, or capital change, the most suitable general category for a material, non-standard announcement is RNS (Regulatory Filings/Miscellaneous). I will classify it as RNS as it is a specific clinical update that doesn't fit the other specific categories like ER (financials) or LTR (legal).
2016-03-29 English
Bone Therapeutics annonce les premiers résultats d’efficacité de PREOB® dans l’ostéoporose sévère
Earnings Release Classification · 92% confidence The document is dated March 29, 2016, and is titled "Information réglementée" (Regulated Information). The content announces the first efficacy results of a clinical trial (Phase IIa) for a product called PREOB® in severe osteoporosis patients. This is a press release detailing preliminary clinical trial results and business updates, rather than a comprehensive annual report (10-K), a formal audit report (AR), or a transcript of a call (CT). It is an announcement of financial/operational news. Since it is a specific announcement of results and business progress, it fits best under the general category of an Earnings Release (ER) if it were quarterly results, but since it is clinical trial data, it is a significant operational update. Given the options, this type of press release announcing key operational/clinical milestones, often released outside of standard quarterly reporting cycles, is frequently classified as an Earnings Release (ER) if it contains key performance indicators, or sometimes as Regulatory Filing (RNS) if it's a mandatory disclosure without a better fit. However, the content is a direct announcement of results, similar in function to an ER announcing performance highlights. Since it is not a full report, and it is a specific announcement, ER is the closest fit for a material operational update, although RNS is a possibility if it's purely regulatory disclosure. Given the structure and focus on 'results' and 'announces,' ER is chosen as the primary operational announcement type, though it is not strictly 'earnings.' If we consider the context of a biotech company, clinical trial updates are often treated as material event disclosures, which often fall under ER or RNS. Given the strong focus on announcing positive results, ER is a strong candidate for a material operational update announcement. Q1 2016
2016-03-29 French
Bone Therapeutics rapporteert initiële doeltreffendheidsresultaten van de PREOB® Fase IIA studie in ernstige osteoporose
Legal Proceedings Report Classification · 99% confidence The document is titled with a date and the header "Gereglementeerde informatie" (Regulated information). The content announces initial efficacy results from a Phase IIA clinical study for a product called PREOB® in severe osteoporosis. It details preliminary data on pain reduction and bone regeneration markers, includes quotes from the CEO, and provides extensive background on the drug, the condition, and the company. This structure—announcing specific, time-sensitive clinical trial results outside of a full periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses purely on operational/clinical results and not necessarily the full quarterly financials (which would suggest IR or ER), and given the nature of announcing specific clinical milestones, it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less detailed. However, the detailed nature of the results presentation strongly suggests it is the primary announcement of period performance/milestones, aligning with the 'ER' definition (Initial announcement of periodical financial results/key highlights). Since it is a detailed announcement of clinical progress, which often accompanies or substitutes for a traditional earnings release in biotech, ER is the most appropriate fit among the specific options, as it is not a full report (10-K, IR) nor a general regulatory filing (RNS) without a more specific category.
2016-03-29 Dutch
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 99% confidence The document is a press release dated March 16, 2016, announcing that the company will release its 'full year results for the year ending 31 December 2015' on March 29, 2016. It also provides details for an accompanying conference call. Since this document is an announcement about the future release of financial results (the full year results) and includes conference call details, it fits the definition of an Earnings Release (ER) or potentially a Report Publication Announcement (RPA). Given that it explicitly states the date the results will be announced and provides the mechanism (conference call) to discuss them, it functions as the initial communication of the period's financial performance highlights, aligning best with the Earnings Release (ER) category, which covers initial announcements of periodical financial results. It is not the full report itself (10-K) nor is it solely an announcement of the report's publication date without context (RPA).
2016-03-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.